SOFINNOVA-PARTNERS
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today three new investments from the Sofinnova Telethon Fund, its early-stage fund dedicated to investments in rare, genetic diseases. The startups, AAVantgarde Bio , Alia Therapeutics , and Borea Therapeutics , are developing promising new therapies for rare, genetic diseases.
Graziano Seghezzi, Managing Partner at Sofinnova Partners, commented: “These investments mark an important step in our mission to support the excellent scientific research coming out of Italian academic and research centers. They also highlight the exceptional flow of new investment opportunities in Italian biotech, and the important role that venture capital plays in enabling ground-breaking treatments to reach patients suffering from rare, genetic diseases who today have very few therapeutic options.”
The Sofinnova Telethon Fund is the largest fund entirely dedicated to biotechnology in Italy. The team is led by technology transfer specialists Lucia Faccio and Paola Pozzi, Partners at Sofinnova Partners, who are based in the firm’s Milan office.
The three new seed investments, totaling €6M, align with the fund’s investment strategy to seek out and support the best Italian science and the most promising entrepreneurs to develop world-class companies in the field of rare, genetic diseases.
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy. The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. Existing AAV-based platforms have been limited by capacity, and AAVantgarde Bio responds to this challenge by enabling delivery of large genes to tissue and cells in vivo. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.
Alia Therapeutics, based in Trento, is developing next generation CRISPR-based medicine for safer on-target in vivo gene editing approaches to the treatment of retinal degeneration. Alia is a spin-off of the University of Trento and was accelerated at BiovelocITA, Italy’s first biotechnology accelerator co-founded in 2015 by Sofinnova Partners and two serial entrepreneurs, Silvano Spinelli and Gabriella Camboni. It is the second company to emerge from the accelerator, following the success of Enthera Pharmaceuticals, another Italian startup that is part of Sofinnova Partners’ portfolio. This round of financing also included participation from BiovelocITA, Indaco Venture Partners, and a group of Italian investors brought together by Banor SIM and Banca Profilo.
Ms. Pozzi, Partner at Sofinnova Partners, board member of AAVantgarde Bio and an investment partner in Alia Therapeutics, commented: “We are delighted to support these innovative biotech startups as they advance promising programs towards preclinical and clinical development. Both companies have highly qualified scientific teams with globally recognized expertise in the field of gene therapy and gene editing. We are confident in the potential of these companies to tackle the limitations of existing therapies and develop treatments to diseases that do not have adequate solutions today.”
Borea Therapeutics, based in Milan, is advancing a new generation of gene therapies that would enable targeting of specific tissues and cells. The company’s innovative technology could enable viral vectors to reach areas like the central nervous system (CNS) and peripheral nervous system (PNS), thus opening the door to new therapeutic options. Borea Therapeutics was co-founded by Professor Paul Heppenstall and the European Molecular Biology Lab (EMBL), an intergovernmental research organization with six research sites throughout Europe, including one in Rome. The company’s research activities are performed in collaboration with Scuola Internazionale Superiore di Studi Avanzati (SISSA), a scientific center of excellence in Trieste.
Ms. Faccio, Partner at Sofinnova Partners and a board member of Borea Therapeutics, commented: “One of the major limitations of gene therapy is the difficulty of selectively targeting specific cells or tissues. Borea Therapeutics’ technology has the potential to pinpoint specific tissues and cells, which would enable the use of lower doses, making treatment safer and more effective for patients. This could be the next breakthrough in gene therapy.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom